Skip to main content
SpringerLink
Log in

Chemotherapy of breast cancer

  • Published:
Medical Oncology and Tumor Pharmacotherapy Aims and scope Submit manuscript

Abstract

Carcinoma of the breast will prove fatal to over 37,000 women in the United States in 1983, despite attempts at early diagnosis.

Hormonal manipulation, known to provide effective palliation for many years, can now be effectively aimed at receptor positive women who have a 50–70% chance of responding. Newer agents, such as tamoxifen and aminoglutethimide offer the benefits of older treatments with less morbidity. Investigations of drugs acting at the level of the central nervous system are ongoing.

Single agent chemotherapy is clearly effective in causing tumor regression, but effective combination chemotherapy provides more responses and a longer duration of response. The most effective combination regimens at present contain doxorubicin. Pharmacologic studies at the cellular level can be expected to provide more effective combinations.

The most effective way to combine hormonal and chemotherapeutic treatments is not known. In receptor positive women without life-threatening disease, beginning with hormonal treatment may be effective in providing palliation at low toxic cost without jeopardizing overall survival. New efforts to cure clinically manifest metastatic breast cancer may eschew palliation as a prime goal. Techniques of synchronizing and of stimulating breast cancer to increase its susceptibility to cytotoxic drugs are under investigation.

Immunotherapy is not established as a beneficial modality in the treatment of breast cancer, although levamisole has led to suggestive benefit in small controlled trials.

The use of chemotherapy, and possibly of some hormonal treatments in appropriate patients, as an adjuvant to surgery prolongs disease-free survival. This approach, using established chemotherapeutic and hormonal agents when the metastatic disease is subclinical, is consonant with abundant evidence from experimental systems and other human cancers that are curable. Expectation of curing human breast cancer will likely require aggressive action at the time when the total body tumor burden is at a minimum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silverberg E: Cancer statistics, 1983.Ca-A Cancer J for clin 33, 9 (1983).

    Article  CAS  Google Scholar 

  2. Perlow L, Holland J F: Chemotherapy of breast cancer, in Deppe G. (ed):Chemotherapy of Gynecologic Cancer. New York, Alan A. Liss, (in press).

  3. Osborne C, Yochmowitz M, Knight W, McGuire W: The value of estrogen and progesterone receptors in the treatment of breast cancer.Cancer 40 (Suppl), 2884 (1980).

    Article  Google Scholar 

  4. Lippman M, Allegra J: Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval.Cancer 46 (Suppl), 2829 (1980).

    Article  PubMed  CAS  Google Scholar 

  5. Dao T, Nemoto T: Steroid receptors and response to endocrine ablations in women with metastatic cancer of the breast.Cancer 46 (Suppl), 2779 (1980).

    Article  PubMed  CAS  Google Scholar 

  6. Manni A, Arafah B, Pearson O: Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy.Cancer 46 (Suppl), 2838 (1980).

    Article  PubMed  CAS  Google Scholar 

  7. Johnson P, Bonomi P, Anderson K, Walter J, Rossof A, Economou S: Megestrol acetate (MA) in advanced breast cancer: response rate related to estrogen receptor (ER) and progesterone receptor (PR) levels.Proc ASCO 1, 89 (1982).

    Google Scholar 

  8. Rubens R, Hayward J: Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer.Cancer 46 (Suppl), 2922 (1980).

    Article  PubMed  CAS  Google Scholar 

  9. Young P, Ehrlich C, Einhorn L: Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer.Cancer 46 (Suppl), 2961 (1980).

    Article  PubMed  CAS  Google Scholar 

  10. Paridaens R, Sylvester R, Ferrazzi E, Legros N, Leclercq G, Henson J: Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer.Cancer 46 (Suppl), 2889 (1980).

    Article  PubMed  CAS  Google Scholar 

  11. McFarlane J, Fleiszer D, Fazekas A: Studies on estrogen receptors and regression in human breast cancer.Cancer 45, 2998 (1980).

    Article  Google Scholar 

  12. Skinner L, Barnes D, Ribeiro G: The clinical value of multiple steroid receptor assays in breast cancer management.Cancer 46, 2939 (1980).

    Article  PubMed  CAS  Google Scholar 

  13. Leake R, Laing L, Calman K, Macbeth F, Crawford D, Smith D: Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.Br J Cancer 43, 59 (1981).

    PubMed  CAS  Google Scholar 

  14. Degenshein G, Bloom N, Tobin E: The value of progesterone receptor assays in the management of advanced breast cancer.Cancer 46 (Suppl), 2789 (1980).

    Article  PubMed  CAS  Google Scholar 

  15. Bloom N, Tobin E, Schreibman B, Degenshein G: The role of progesterone receptors in the management of advanced breast cancer.Cancer 45, 2992 (1980).

    Article  PubMed  CAS  Google Scholar 

  16. Sarrif A, Durant J: Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor.Cancer 48, 1215 (1981).

    Article  PubMed  CAS  Google Scholar 

  17. Johnson P, Bonomi P, Bacon L, Walter J, Anderson K, Economou S: Quantitative progesterone receptor level as a predictor of response to megestrol acetate or tamoxifen in advanced breast cancer.Proc ASCO 2, 108 (1983).

    Google Scholar 

  18. Paridaens R, Leclercq G, Legros N, Sylvester R, Henson J, Toma S: Estrogen receptor variation in neoplastic tissue during the course of disease in patients with recurrent breast cancer.Proc AACR 23, 151 (1982).

    Google Scholar 

  19. Holdaway I, Bowditch J: Variation in receptor status between primary and metastatic breast cancer.Cancer 52, 479 (1983).

    Article  PubMed  CAS  Google Scholar 

  20. Gross G, Clark G, McGuire W: Multiple progesterone (PR) assays in human breast cancer.Proc ASCO 2, 110 (1983).

    Google Scholar 

  21. Kennedy B, Fortuny I: Therapeutic castration in the treatment of advanced breast cancer.Cancer 17, 1197 (1964).

    Article  PubMed  CAS  Google Scholar 

  22. Harris H, Spratt J: Bilateral adrenalectomy in metastatic mammary cancer: an analysis of sixty-four cases.Cancer 23, 145 (1969).

    Article  PubMed  Google Scholar 

  23. Fracchia A, Randall H, Farrow J: The results of adrenalectomy in advanced breast cancer in 500 consecutive patients.Surg Gynec Obs 125, 747 (1967).

    CAS  Google Scholar 

  24. Manni A, Pearson O, Brodkey J, Marshall J: Transphenoidal hypophysectomy in breast cancer: evidence for an individual role of pituitary and gonadal hormones in supporting tumor growth.Cancer 44, 2330 (1979).

    Article  PubMed  CAS  Google Scholar 

  25. Council on Drugs, Subcommittee on Breast and Genital Cancer, Committee on Research, AMA. Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients.J Am Med Assoc 172, 1271 (1960).

    Google Scholar 

  26. Kennedy B: Hormone therapy for advanced breast cancer.Cancer 18, 1551 (1965).

    Article  PubMed  CAS  Google Scholar 

  27. Cooperative Breast Cancer Group. Results of studies of the Cooperative Breast Cancer Group, 1961–63.Cancer Chemo Rep 41 (Suppl) 1 (1964).

    Google Scholar 

  28. Carter A, Sedransk N, Kelley R, Ansfeld F, Ravdin R, Talley R, Potter N: Diethylstilbestrol—recommended dosages for different categories of breast cancer patients: Report of the Cooperative Breast Cancer Group.J Am Med Assoc 237, 2079 (1977).

    Article  CAS  Google Scholar 

  29. Ingle J, Ahmann D, Green S, Edmonson J, Bisel H, Krols L, Nichols W, Creagan E, Hahn R, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with advanced breast cancer.New Engl J Med 304, 16 (1981).

    PubMed  CAS  Google Scholar 

  30. Westerberg H: Tamoxifen and fluoxymesterone in advanced breast cancer. A controlled clinical trial.Cancer Treat Rep 64, 117 (1980).

    PubMed  CAS  Google Scholar 

  31. Tormey D, Gelman R, Band P, Sears M, Bauer M, Arseneau J, Falkson G: A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer.Breast Cancer Res Treat 1, 111 (1981).

    Article  PubMed  CAS  Google Scholar 

  32. Manni A, Pearson O: Antiestrogen-induced remission in premenopausal women with Stage IV breast cancer: effects on ovarian function.Cancer Treat Rep 64, 779 (1980).

    PubMed  CAS  Google Scholar 

  33. Pritchard K, Thomson D, Myers R, Sutherland D, Mobbs B, Meakin J: Tamoxifen therapy in premenopausal patients with metastatic breast cancer.Cancer Treat Rep 64, 787 (1980).

    PubMed  CAS  Google Scholar 

  34. Hoogstraten B, Fletcher W, Gad-el-Mawla N, Maloney T, Altman S, Vaughn C, Foulkes M: Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: a Southwest Oncology Group Study.Cancer Res 42, 4788 (1982).

    PubMed  CAS  Google Scholar 

  35. Beex L, Pieters G, Koenders A, Benraad T, Kloppenborg P: Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.Cancer Treat Rep 65, 179 (1981).

    PubMed  CAS  Google Scholar 

  36. Legha S, Carter S: Antiestrogens in the treatment of breast cancer.Cancer Treat Rep 3, 205 (1976).

    Article  CAS  Google Scholar 

  37. Manni A, Arafah B: Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature.Cancer 48, 873 (1981).

    Article  PubMed  CAS  Google Scholar 

  38. Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E: Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.Cancer 48, 876 (1981).

    Article  PubMed  CAS  Google Scholar 

  39. Santen R, Worgul T, Lipton A, Harvey H, Boucher A, Samojlik E, Wells S: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.Ann Int Med 96, 94 (1982).

    PubMed  CAS  Google Scholar 

  40. Asbury R, Bakemeier R, Folsch E, McCune C, Savlov E, Bennett J: Treatment of metastatic breast cancer with aminoglutethimide.Cancer 47, 1954 (1981).

    Article  PubMed  CAS  Google Scholar 

  41. Santen R, Worgul T, Samojlik E, Interrante A, Boucher A, Lipton A, Harvey H, White D, Smart E, Cox C, Wells S: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.New Engl J Med 305, 545 (1981).

    PubMed  CAS  Google Scholar 

  42. Lipton A, Harvey H, Santen R, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A: A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.Cancer 50, 2265 (1982).

    Article  PubMed  CAS  Google Scholar 

  43. Nagel G, Wander H, Blossey H C: Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer.Cancer Res 42, (Suppl), 3442 (1982).

    Google Scholar 

  44. Alexiera-Figusch J, van Gilse H, Hop W, Phoa C, Wijst S, Treurniet R: Progestin therapy in advanced breast cancer: megestrol acetate—an evaluation of 160 treated cases.Cancer 46, 2369 (1980).

    Article  Google Scholar 

  45. Pannuti F, Martoni A, Lenaz G, Piana E, Nanni P: A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.Cancer Treat Rep 62, 499 (1978).

    PubMed  CAS  Google Scholar 

  46. Izuo M, Iino Y, Endo K: Oral high dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer.Breast Cancer Res Treat 1, 125 (1981).

    Article  PubMed  CAS  Google Scholar 

  47. Wander H, Blossey C, Koberling J, Nagel G: High dose medroxyprogesterone acetate in metastatic breast cancer: correlations between tumor response and endocrine parameters.Klin Wochensch (in press).

  48. Pellegrini A, Massidda B, Mascia V, Ionta M, Lippi M, Muggiano A, Carboni E, della Cuna G, Bernardo G, Strada M, Pavesi L: Ethinyl estradiol and medroxyprogesterone treatments in advanced breast cancer: a pilot study.Cancer Treat Rep 65, 135 (1981).

    PubMed  CAS  Google Scholar 

  49. Klijn J, De Jong F: Treatment with a luteinizing hormone-releasing hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer.Lancet i 1213 (1982).

    Article  Google Scholar 

  50. Harvey H, Lipton A, Santen R, Escher G, Hardy M, Glade L, Segaloff A, Landan R, Schreier H, Max D: Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients.Proc ASCO 22, 444 (1981).

    Google Scholar 

  51. Paladine W, Ayres V, Price L, Drapkin R, Sokol G, Kriz E, Scheinbaum M: Danazol, an inhibitor of LH and FSH in the treatment of recurrent or metastatic breast carcinoma.Proc ASCO 22, 447 (1981).

    Google Scholar 

  52. Nagel G, Holtkamp W, Wander H, Blossey C: Hyperprolactinemia and bromocryptine in metastatic breast cancer.Proc AACR 22, 139 (1982).

    Google Scholar 

  53. Nemoto T, Dao T: 5-fluorouracil and cyclophosphamide in disseminated breast cancer.N Y State J Med 71, 554 (1971).

    PubMed  CAS  Google Scholar 

  54. Bull J, Tormey D, Li S, Carbone P, Falkson G, Blom J, Perlin E, Simon R: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.Cancer 41, 1649 (1978).

    Article  PubMed  CAS  Google Scholar 

  55. Swenerton K, Legha S, Smith T, Hortobagyi G, Gehan E, Yap H, Gutterman J, Blumenschein G: Prognostic factors in metastatic breast cancer treated with combination chemotherapy.Cancer Res 39, 1552 (1979).

    PubMed  CAS  Google Scholar 

  56. Nash C, Jones S, Moon T, Davis S, Salmon S: Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy.Cancer 46, 2380 (1980).

    Article  PubMed  Google Scholar 

  57. Tormey D: Single agent chemotherapy and comparison with combination therapy in advanced breast cancer.Ann Int Med 86, 784 (1977).

    Google Scholar 

  58. Manni A, Trujillo J, Pearson O: Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.Cancer Treat Rep 64, 111 (1980).

    PubMed  CAS  Google Scholar 

  59. Legha S, Buzdar A, Smith T, Swenerton K, Hortobagyi G, Blumenschein G: Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy.Cancer 46, 438 (1980).

    Article  PubMed  CAS  Google Scholar 

  60. Steiner R, Stewart J, Rubens R: Does response to endocrine therapy predict response to chemotherapy in advanced breast cancer?Proc AACR 23, 143 (1982).

    Google Scholar 

  61. Lippman M, Allegra J, Thompson E, Simon R, Barlock A, Green L, Huff K, Do H, Aitken S, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.New Engl J Med 298, 1223 (1978).

    PubMed  CAS  Google Scholar 

  62. Kiang D, Frenning D, Gay J, Goldman A, Kennedy B: Estrogen receptor status and response to chemotherapy in advanced breast cancer.Cancer 46 (Suppl), 2814 (1980).

    Article  PubMed  CAS  Google Scholar 

  63. Mortimer J, Reimer R, Greenstreet R, Groppe C, Bukowski R: Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer.Cancer Treat Rep 65, 763 (1981).

    PubMed  CAS  Google Scholar 

  64. Chang J, Wergowske G: Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in advanced breast cancer.Cancer 48, 2503 (1981).

    Article  PubMed  CAS  Google Scholar 

  65. Jonat W, Maass H, Stolzenbach G, Trams G: Estrogen receptor status and response to polychemotherapy in advanced breast cancer.Cancer 46 (Suppl), 2809 (1980).

    Article  PubMed  CAS  Google Scholar 

  66. Hilf R, Feldstein M, Savlov E, Gibson S, Seneca B: The lack of relationship between estrogen receptor status and response to chemotherapy.Cancer 46 (Suppl), 2797 (1980).

    Article  PubMed  CAS  Google Scholar 

  67. Holland J F: Breaking the cure barrier.J Clin Onc 1, 75 (1983).

    CAS  Google Scholar 

  68. Carter S: Single and combination nonhormonal chemotherapy in breast cancer.Cancer 30, 1543 (1972).

    Article  PubMed  CAS  Google Scholar 

  69. Coggins P, Eisman S, Elkins W, Ravdin R: Cyclophosphamide therapy in carcinoma of the breast and ovary—a comparative study of intermittent massive vs continuous maintenance dosage regimens.Cancer Chemo Rep 15, 3 (1961).

    CAS  Google Scholar 

  70. Stoll B: Evaluation of cyclophosphamide dosage schedules in breast cancer.Br J Cancer 24, 478 (1970).

    Google Scholar 

  71. Skipper H, Schabel F, Wilcox W: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia.Cancer Chemo Rep 35, 1 (1964).

    CAS  Google Scholar 

  72. Moore G, Bross D, Ausman R, Nadler S, Jones R, Slack N, Rimm H: Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer: Eastern Clinical Drug Evaluation Program.Cancer Chemo Rep (Part 1) 52, 661 (1968).

    CAS  Google Scholar 

  73. Zubrod C: Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide.J Chron Dis 11, 7 (1966).

    Article  Google Scholar 

  74. Hurley J: A method of selecting patients for cancer chemotherapy.Arch Surg 83, 611 (1961).

    PubMed  CAS  Google Scholar 

  75. Sears M, Haut A, Eckles N: Melphalan (NSC-8806) in advanced breast cancer.Cancer Chemo Rep 50, 271 (1966).

    CAS  Google Scholar 

  76. Canellos G, Pocock S, Taylor S, Sears M, Klaasen D, Band P: Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy withl-phenylalanine mustard.Cancer 38, 1882 (1976).

    Article  PubMed  CAS  Google Scholar 

  77. Curreri A, Ansfield F, McIver F, Waisman H, Heidelberger C: Clinical studies with 5-fluorouracil.Cancer Res 18, 478 (1958).

    PubMed  CAS  Google Scholar 

  78. Ansfield F: A less toxic fluorouracil dosage schedule.J Am Med Assoc 190, 686 (1964).

    CAS  Google Scholar 

  79. Jacobs E, Reeves W, Wood D: Treatment of cancer with weekly intravenous 5-fluorouracil.Cancer 27, 1302 (1971).

    Article  PubMed  CAS  Google Scholar 

  80. Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H, Cornell G: A Phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report.Cancer 39, 34 (1977).

    Article  PubMed  CAS  Google Scholar 

  81. Chlebowski R, Pugh R, Weiner J, Bateman J: Treatment of advanced breast cancer with 5-fluorouracil: a randomized comparison of two routes of delivery.Cancer 48, 1711 (1981).

    Article  PubMed  CAS  Google Scholar 

  82. Talley R, Vaitkevicius V, Leighton G: Comparison of cyclophosphamide and 5-fluorouracil in the treatment of patients with metastatic breast cancer.Clin Pharm Ther 6, 740 (1965).

    CAS  Google Scholar 

  83. Yap H, Blumenschein G, Yap B, Hortobagyi G, Tashima C, Waring A, Benjamin R, Bodey G: High-dose methotrexate for advanced breast cancer.Cancer Treat Rep 63, 757 (1979).

    PubMed  CAS  Google Scholar 

  84. Capizzi R: Improvement in the therapeutic index of methotrexate (NSC-740) byl-asparaginase (NSC-109229).Cancer Chemo Rep (Part 3),6, 37 (1975).

    CAS  Google Scholar 

  85. Yap H, Benjamin R, Blumenschein G, Hortobagyi G, Tashima C, Buzdar A, Bodey G: Phase II study with sequentiall-asparaginase and methotrexate in advanced refractory breast cancer.Cancer Treat Rep 63, 77 (1979).

    PubMed  CAS  Google Scholar 

  86. Holland J F, Scharlan C, Gailani S, Krant M, Olson K, Horton J, Schnider B, Lynch J, Owens A, Carbone P, Colsky J, Grob D, Miller S, Hall T: Vincristine treatment of advanced cancer: a cooperative study of 392 cases.Cancer Res 33, 1258 (1973).

    PubMed  CAS  Google Scholar 

  87. Grinberg R, Nemoto T, Dao T: Vincristine (NSC-67574): dosage and response in advanced breast cancer.Cancer Chemo Rep 45, 57 (1965).

    CAS  Google Scholar 

  88. Yap H, Blumenschein G, Keating M, Hortobagyi G, Tashima C, Loo T: Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.Cancer Treat Rep 64, 279 (1980).

    PubMed  CAS  Google Scholar 

  89. Fraschini G, Yap H, Barnes B, Buzdar A, Hortobagyi H, Blumenschein G: Continuous 5-day infusion of vinblastine for refractory metastatic breast cancer.Proc ASCO 1, 78 (1982).

    Google Scholar 

  90. Tannock I, Erlichman C, Perrault D, Quirt I, King M: Failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory breast cancer.Cancer Treat Rep 66, 1783 (1982).

    PubMed  CAS  Google Scholar 

  91. White D, Hopkins J, Jackson D, Muss H, Richards F, Cooper M, Stuart J, Spurr C: Vincristine by continuous infusion in refractory breast cancer: a phase II study.Proc ASCO 1, 83 (1982).

    Google Scholar 

  92. Walker B, Raich P, Fontana J, Subramanian V, Rogers J, Knost J, Denning B: Phase II study of vindesine in patients with advanced breast cancer.Cancer Treat Rep 66, 1729 (1982).

    PubMed  CAS  Google Scholar 

  93. Smith I, Hedley D, Powles T, McElwain T: Vindesine: a Phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors.Cancer Treat Rep 62, 1427 (1978).

    PubMed  CAS  Google Scholar 

  94. Cobleigh M, Williams S, Einhorn L: Phase II study of vindesine in patients with metastatic breast cancer.Cancer Treat Rep 65, 659 (1981).

    PubMed  CAS  Google Scholar 

  95. Yap H, Blumenschein G, Bodey G, Hortobagyi G, Buzdar A, DiStefano A: Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.Cancer Treat Rep 65, 775 (1981).

    PubMed  CAS  Google Scholar 

  96. Tormey D: A driamycin (NSC-123127) in breast cancer: an overview of studies.Cancer Chemo Rep (Part 3),6, 319 (1975).

    Google Scholar 

  97. Hoogstraten B, George S, Samal B, Rivkin S, Costanzi J, Bonnet J, Thigpen T, Braine H: Combination chemotherapy and adriamycin in patients with advanced breast cancer: a Southwest Oncology Group Study.Cancer 38, 13 (1976).

    Article  PubMed  CAS  Google Scholar 

  98. Gottlieb J, Rivkin S, Spigel S, Hoogstraten B, O'Bryan R, Delaney F, Singhakowinta A: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast cancer: a Southwest Cancer Chemotherapy Group Study.Cancer 33, 519 (1974).

    Article  PubMed  CAS  Google Scholar 

  99. Knight E, Horton J, Cunningham T, Rhie F, Lagakos S, Rosenbaum C, Taylor S, Tennant J: Adriamycin: comparison of a 5-week schedule with a 3-week schedule in the treatment of breast cancer.Cancer Treat Rep 63, 121 (1979).

    PubMed  CAS  Google Scholar 

  100. Ingle J, Ahmann D, O'Fallon J, Bisel H, Rubin J, Krols L, Guiliano E: Randomized Phase II trial of rubidazone and adriamycin in women with advanced breast cancer.Cancer Treat Rep 63, 1701 (1979).

    PubMed  CAS  Google Scholar 

  101. Nemoto T, Rosner D, Diaz R, Dao T, Sponzo R, Cunningham T, Horton J, Simon R: Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytotoxan and prednisone with adriamycin or adrenalectomy.Cancer 41, 2073 (1978).

    Article  PubMed  CAS  Google Scholar 

  102. Creech R, Catalano R, Shah M: An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients.Cancer 46, 433 (1980).

    Article  PubMed  CAS  Google Scholar 

  103. Creech R, Catalano R, Hopson R: A comparison of standard dose adriamycin (SDA) and low dose adriamycin (LDA) as primary chemotherapy for metastatic breast cancer.Proc AACR 21, 142 (1980).

    Google Scholar 

  104. Legha S, Benjamin R, Mackay B, Yap H, Wallace S, Ewer M, Blumenschein G, Freireich E: Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer.Cancer 49, 1762 (1982).

    Article  PubMed  CAS  Google Scholar 

  105. Ahmann D, Bisel H, Eagan R, Edmonson T, Hahn R: Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.Cancer Chemo Rep 58, 877 (1979).

    Google Scholar 

  106. Jones R, Norton L, Bhardwaj S, Mass T, Holland J: Single agent adriamycin for metastatic breast cancer. A steep dose-response relationship.Proc ASCO 2, 107 (1983).

    Google Scholar 

  107. Stuart-Harris R, Smith I: Mitoxantrone: a Phase II study in the treatment of patients with advanced breast carcinoma and other solid tumors.Cancer Chemo Pharm 8, 179 (1982).

    CAS  Google Scholar 

  108. Knight W, Von Hoff D, Tranum B, O'Bryan R: A Phase II trial of dihydroxyanthracenedione (DHAD, mitoxantrone) in breast cancer: a Southwest Oncology Group (SWOG) Study,Proc ASCO 1, 87 (1982).

    Google Scholar 

  109. Stuart-Harris R, Smith I, Cornbleet M, Smyth J, Rubens R: Mitoxantrone, an active well tolerated new drug in advancing breast cancer: a Phase II study in patients receiving no previous chemotherapy.Proc ASCO 2, 100 (1983).

    Google Scholar 

  110. Osborne C, Von Hoff D, Sandback J: Activity of bisantrene in a Phase II study in advanced breast cancer.Proc. ASCO 1, 87 (1982).

    Google Scholar 

  111. Yap H, Yap B, Blumenschein G, Barnes B, Schell F, Bodey G: Bisantrene, an active new drug in the treatment of metastatic breast cancer.Cancer Res 43, 1402 (1983).

    PubMed  CAS  Google Scholar 

  112. Moore G, Bross D, Ausman R, Nadler S, Jones R, Slack N, Rimm A: Effects of mitomycin C (NSC-26980) in 346 patients with advanced cancer. Eastern Clinical Oncology Evaluation Program.Cancer Chemo Rep (Part I)52, 675 (1968).

    CAS  Google Scholar 

  113. Creech R, Catalano R, Shah M, Dayal H: A randomized trial of adriamycin vs mitomycin at low doses in CMF refractory metastatic breast cancer patients.Proc ASCO 1, 88 (1982).

    Google Scholar 

  114. Currie V, Howard J, Wittes R: A Phase II evaluation ofm-AMSA, 4′-(9-acridinylamino)methanesulfon-m-anisidide, in patients with breast cancer.Cancer Clin Trials 4, 249 (1981).

    PubMed  CAS  Google Scholar 

  115. Legha S, Blumenschein G, Buzdar A, Hortobagyi G, Bodey G: Phase II study of 4′-(9-acridinylamino) methane-sulfon-m-anisidide (AMSA) in metastatic breast cancer.Cancer Treat Rep 63, 1961 (1979).

    PubMed  CAS  Google Scholar 

  116. Ahmann D, Bisel H, Bacon R, Edmonson J, Hahn R, O'Connell M, Frytak S: Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.Cancer Treat Rep 60, 633 (1976).

    PubMed  CAS  Google Scholar 

  117. Vaughn L, Panettiere F, Thigpen T, Bottomley R, Hoogstraten B, Samal B: Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.Cancer Treat Rep 65, 443 (1981).

    PubMed  CAS  Google Scholar 

  118. Yap H, Blumenschein G, Schnell F, Bodey G: Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer.Cancer Treat Rep 65, 465 (1981).

    PubMed  CAS  Google Scholar 

  119. Yap H, Salem P, Hortobagyi G, Bodey G, Buzdar A, Tashima C, Blumenschein G: Phase II study ofcis-dichlorodiammineplatinum (II) in advanced breast cancer.Cancer Treat Rep 62, 405 (1978).

    PubMed  CAS  Google Scholar 

  120. Shingleton W, Sedranks N, Johnson R: Systemic chemotherapy of mammary carcinoma.Ann Surg 173, 913 (1971).

    Article  PubMed  CAS  Google Scholar 

  121. Denefrio J, Vogel C: Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.Cancer Treat Rep 62, 173 (1978).

    PubMed  CAS  Google Scholar 

  122. Legha S, Buzdar A, Hortobagyi G, Di Stefano A, Wiseman C, Yap H, Blumenschein G, Bodey G: Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.Cancer Treat Rep 63, 2053 (1979).

    PubMed  CAS  Google Scholar 

  123. Fabian C, Rasmussen S, Stephens R, Haut A, Smith F, Balcerzak S, Tranum B: Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group Study.Cancer Treat Rep 63, 1359 (1977).

    Google Scholar 

  124. Forestiere A, Hakes T, Wittes J, Wittes R: Cisplatin in the treatment of metastatic breast carcinoma. A prospective randomized trial of two dosage schedules.Am J Clin Oncol 5, 243 (1982).

    Article  Google Scholar 

  125. Blum R, Frei E, Holland J F: Principles of dose schedule and combination chemotherapy, in Holland J and Frei E (eds)Cancer Medicine, pp. 730–752, Philadelphia, Lea & Feibiger (1982).

    Google Scholar 

  126. Greenspan E: Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma.J Mt Sinai Hosp 33, 1 (1966).

    CAS  Google Scholar 

  127. Leone L, Falkson G, Glidewell O, Holland J F: CALGB unpublished data.

  128. Cooper R: Combination chemotherapy in hormone resistant breast cancer.Proc AACR 10, 15 (1969).

    Google Scholar 

  129. Davis H, Ramirez G, Ellerby R, Ansfield F: Five-drug therapy in advanced breast cancer. Factors, influences, toxicity and response.Cancer 34, 239 (1974).

    Article  PubMed  Google Scholar 

  130. Smalley R, Murphy S, Huguley C, Bartolucci A: Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.Cancer Res 36, 3911 (1976).

    PubMed  CAS  Google Scholar 

  131. Perloff M, Norton L, Bushkin E, Holland J: Intensive six-week courses of combination chemotherapy in Stage IV breast carcinoma.Proc ASCO 1, 73 (1982).

    Google Scholar 

  132. Ahmann D, Bisel H, Hahn R, Eagan T, Edmonson J, Steinfeld J, Tormey D, Taylor W: An analysis of a multiple drug program in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphamide and prednisone with or without vincristine.Cancer 36, 1925 (1975).

    Article  PubMed  CAS  Google Scholar 

  133. Tormey D, Gelman R, Band P, Sears M, Rosenthal S, De Wys W, Perlia C, Rice M: Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.Cancer 50, 1235 (1982).

    Article  PubMed  CAS  Google Scholar 

  134. Chlebowski R, Pugh R, Weiner J, Block J, Bateman J: Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer: a randomized trial.Cancer 52, 606 (1983).

    Article  PubMed  CAS  Google Scholar 

  135. Canellos G P, DeVita V T, Gold G L, Chasner B, Schein P S, Young R C: Combination chemotherapy for advanced breast cancer: Response and effect on survival.Ann Int Med 84, 389 (1976).

    PubMed  CAS  Google Scholar 

  136. Creech R, Catalano R, Mastrangelo M, Engstrom P: An effective low-dose intermittent cyclophosphamide, methotrexate and 5-fluorouracil treatment regimen for metastatic breast cancer.Cancer 35, 1101 (1975).

    Article  PubMed  CAS  Google Scholar 

  137. Jones S, Dupre B, Salmon S: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.Cancer 36, 90 (1975).

    Article  PubMed  CAS  Google Scholar 

  138. Tranum B, McDonald B, Thigpen T, Vaughn C, Wilson H, Maloney T, Costanzi J, Bickers J, el Mawli N, Palmer R, Hoogstraten B, Heilburn L, Rasmussen S: Adriamycin combination in advanced breast cancer: a Southwest Oncology Group Study.Cancer 49, 835 (1982).

    Article  PubMed  CAS  Google Scholar 

  139. Lloyd R, Jones S, Salmon S: Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer.Cancer 43, 60 (1979).

    Article  PubMed  CAS  Google Scholar 

  140. Nemoto T, Horton J, Simon R, Dao T, Rosner D, Cunningham R, Sponzo R, Snyderman M: Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5FU and prednisone versus cytoxan and adriamycin versus cytoxan, 5FU and adriamycin versus cytoxan, 5FU and prednisone alternating with cytoxan and adriamycin.Cancer 49, 1988 (1982).

    Article  PubMed  CAS  Google Scholar 

  141. Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G: Response and survival in advanced breast cancer after two non-cross-resistant combinations.Br Med J 1, 801 (1976).

    PubMed  CAS  Google Scholar 

  142. Russell J, Baker J, Dady P, Ford H, Gazet J, McKinna J, Nash A, Powles T: Combination chemotherapy of metastatic breast cancer with vincristine, adriamycin and prednisolone.Cancer 41, 396 (1978).

    Article  PubMed  CAS  Google Scholar 

  143. Rainey J, Jones S, Salmon C: Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC).Cancer 43, 66 (1979).

    Article  PubMed  CAS  Google Scholar 

  144. Carmo-Pereira J, Costa F, Henriques E: Chemotherapy of advanced breast cancer: a randomized trial of vincristine, adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).Cancer 48, 1517 (1981).

    Article  PubMed  CAS  Google Scholar 

  145. Blumenschein G, Cardenas J, Freireich E, Gottlieb J: FAC chemotherapy for breast cancer.Proc Am Assoc Clin Oncol 10, 193 (1974).

    Google Scholar 

  146. Tranum B, Hoogstraten B, Kennedy A, Vaughan C, Samal B, Thigpen T, Rivkin S, Smith F, Palmer R, Costanzi J, Tucker W, Wilson H, Moloney T: Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group Study.Cancer 41, 2078 (1978).

    Article  PubMed  CAS  Google Scholar 

  147. Smalley R, Carpenter J, Bartolucci A, Vogel C, Krauss S: A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.Cancer 40, 625 (1977).

    Article  PubMed  CAS  Google Scholar 

  148. Aisner J, Weinberg V, Perloff M, Weiss R, Raich P, Perry M, Wiernik P: Chemoimmunotherapy for advanced breast cancer: a randomized comparison of 6 combinations (CMF, CAF vs CAFVP) each with or without MER immunotherapy: a CALGB study.Proc ASCO 22, 443 (1981).

    Google Scholar 

  149. Perloff M, Hart R, Holland J: Vinblastine, adriamycin, thiotepa, and halotestin (VATH): therapy for advanced breast cancer refractory to prior therapy.Cancer 32, 2534 (1978).

    Article  Google Scholar 

  150. Hart R, Perloff M, Holland J: One-day VATH (vinblastine, adriamycin, thiotepa, and halotestin) therapy for advanced breast cancer refractory to chemotherapy.Cancer 48, 1522 (1981).

    Article  PubMed  CAS  Google Scholar 

  151. Yap H, Blumenschein G, Hortobagyi G, Bodey G: Mitoxantrone, cyclophosphamide and 5-fluorouracil in metastatic breast cancer.Proc ASCO 2, 111 (1983).

    Google Scholar 

  152. Rubens R, Knight R, Hayward J: Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.Br J Cancer 32, 730 (1975).

    PubMed  CAS  Google Scholar 

  153. Canellos G, Pocock S, Taylor S, Sears M, Klaasen D, Bard P: Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy with L-phenylalanine mustard.Cancer 38, 1882 (1976).

    Article  PubMed  CAS  Google Scholar 

  154. Baker L, Vaughn C, Al-Sarraf M, Reed M, Vaitkevicius V: Evaluation of combination vs sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.Cancer 33, 513 (1974).

    Article  PubMed  CAS  Google Scholar 

  155. Chlebowski R, Irwin L, Pugh R, Sadoff L, Hestorff R, Wiener J, Bateman J: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy.Cancer Res 39, 4503 (1979).

    PubMed  CAS  Google Scholar 

  156. Abeloff M, Ettinger D: Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.Cancer Treat Rep 61, 1685 (1977).

    PubMed  CAS  Google Scholar 

  157. Tormey D, Gelman R, Falkson G: Prospective evaluation of rotating chemotherapy in advanced breast cancer: an Eastern Cooperative Oncology Group trial.Am J Clin Oncol (CCT)6, 1 (1983).

    Article  CAS  Google Scholar 

  158. Vogel C, Love N, East D, Moore M, Smalley R: Phase II study of alternating cytoreductive and cycle-active combination chemotherapy for metastatic breast cancer.Cancer Treat Rep 63, 2077 (1979).

    PubMed  CAS  Google Scholar 

  159. Blumenschein G, Hortobagyi G, Richman S, Gutterman J, Tashima C, Buzdar A, Burgess M, Livingston R, Hersh E: Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast cancer.Cancer 45, 742 (1980).

    Article  PubMed  CAS  Google Scholar 

  160. Henderson I, Gelman R, Canellos G, Frei E: Prolonged disease-free survival in advanced breast cancer treated with “super-CMF” adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.Cancer Treat Rep 65 (Suppl.), 67 (1981).

    PubMed  Google Scholar 

  161. Cadman E, Heimes R, Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.Science 205 1135 (1979).

    Article  PubMed  CAS  Google Scholar 

  162. Gewirtz A, Cadman E: Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancer.Cancer 47, 2552 (1981).

    Article  PubMed  CAS  Google Scholar 

  163. Herrmann R, Westerhausen M, Bruntsch U, Jungi F, Manegold C, Fritze D: Sequential methotrexate (MTX) and 5-fluorouracil (FU) is effective in extensively pretreated breast cancer.Proc ASCO 1, 86 (1982).

    Google Scholar 

  164. O'Bryan R, Baker L, Gottlieb E, Rivkin S, Balcerzak S, Grumet G, Salman S, Moon T, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia.Cancer 39, 1940 (1977).

    Article  PubMed  Google Scholar 

  165. Perrault D, Erlichman C, Hasselback R, Tannock I, Boyd N: Sequenced methotrexate (MTX) and 5-fluorouracil (5FU) in refractory metastatic breast cancer: a Phase II study.Proc ASCO 2, 100 (1983).

    Google Scholar 

  166. Brunner K, Sonntag R, Alberto P, Senn H, Martz G, Obrecht P, Maurice P: Combined chemo-and hormonal therapy in advanced breast cancer.Cancer 39, 2923 (1977).

    Article  PubMed  CAS  Google Scholar 

  167. Kardinal C: Personal communication (1983).

  168. Krook J, Ingle J, Green S, Bowman W, Duluth M: Randomized trial of cyclophosphamide, 5-fluorouracil, prednisone (CFP) plus or minus tamoxifen (T) in postmenopausal women with advanced breast cancer.Proc ASCO 2, 106 (1983).

    Google Scholar 

  169. Cocconi G, De Lisi V, Boni C, Mori P: CMF vs CMV plus tamoxifen (T) in postmenopausal metastatic breast cancer: a prospective randomized study.Proc ASCO 18, 75 (1982).

    Google Scholar 

  170. Falkson G, Falkson H, Glidewell O, Weinberg V, Leone L, Holland J F: Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study by the Cancer and Leukemia Group B.Cancer 43, 2215 (1979).

    Article  PubMed  CAS  Google Scholar 

  171. Ahmann D, O'Conell M, Hahn R, Bisel H, Lee R, Edmonson J: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy.New Engl J Med 297, 356 (1977).

    PubMed  CAS  Google Scholar 

  172. Ahmann D, Green S, Bisel H, Ingle J: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: a later analysis.Am J Clin Oncol (CCT)5, 355 (1982).

    Article  CAS  Google Scholar 

  173. Glick J, Creech R, Torri S, Holroyde C, Brodovsky H, Catalano R, Varano M: Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.Cancer 45, 735 (1980).

    Article  PubMed  CAS  Google Scholar 

  174. Bezwoda W, Derman D, Moor N, Lange M, Levin J: Treatment of metastatic breast cancer in estrogen receptor positive patients: a randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.Cancer 50, 2747 (1982).

    Article  PubMed  CAS  Google Scholar 

  175. Allegra J, Woodcock T, Richman S, Patel J, Wittliff J: A Phase II evaluation of tamoxifen, premarin, methotrexate (MTX) and 5-fluorouracil (5FU) in stage IV breast cancer.Proc ASCO 22, 441 (1981).

    Google Scholar 

  176. Lippman M, Cassidy J, Wesley M, Young R: A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.Proc ASCO 1, 79 (1982).

    Google Scholar 

  177. Hortobagyi G, Gutterman J, Blumenschein G, Tashima C, Burgess M, Einhorn L, Buzdar A, Richman P, Hersh F: Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide and BCGCancer 44, 1955 (1979).

    Article  PubMed  CAS  Google Scholar 

  178. Muss H, Richards F, Cooper R, White D, Jackson D, Howard V, Shore A, Rhyne A, Spurr C: Chemotherapy vs chemoimmunotherapy with methanol extraction residue of Bacillus Calmette-Guerin (MER) in advanced breast cancer: a randomized trial by the Piedmont Oncology Association.Cancer 47, 2295 (1981).

    Article  PubMed  CAS  Google Scholar 

  179. Hortobagyi G, Gutterman J, Blumenschein G, Yap H, Buzdar A, Tashima C, Burgess M, Hersh E: Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole.Cancer 43, 1112 (1979).

    Article  PubMed  CAS  Google Scholar 

  180. Klefstrom P: Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer.Cancer Treat Rep 64, 65 (1980).

    PubMed  CAS  Google Scholar 

  181. Fisher B, Slack N: Number of lymph nodes examined and the prognosis in breast cancer.Surg Gynec Obst 131, 79 (1970).

    CAS  Google Scholar 

  182. Stenkvist B, Bengtsson E, Dahlquist B, Eklund G, Eriksson O, Jarkrans T, Nordin B: Predicting breast cancer recurrence.Cancer 50, 2884 (1982).

    Article  PubMed  CAS  Google Scholar 

  183. Hager J, Furmanski P, Heppner G, Roi L, Brennan M, Rich M: Breast Cancer Prognostic Study Association: correlation between elevated preoperative CEA levels and early recurrence in breast cancer patients.Proc AACR 23, 144 (1982).

    Google Scholar 

  184. Weigand R, Isenberg W, Russo J, Rich M: Breast Cancer Prognostic Study Association: blood vessel invasion as a prognostic indicator in human breast cancers.Proc AACR 21, 155 (1980).

    Google Scholar 

  185. Black M, Speer F: Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes.Surg Gynec Obst 100, 543 (1955).

    CAS  Google Scholar 

  186. Kinne D, Ashikari R, Butler A, Menendez-Botet C, Rosen P, Schwartz M: Estrogen receptor-protein in breast cancer as a predictor of recurrence.Cancer 47, 2364 (1981).

    Article  PubMed  CAS  Google Scholar 

  187. Blamey R, Bishop H, Blake J, Doyle P, Elston C, Haybittle J, Nicholson R, Griffiths K: Relationship between primary breast tumor receptor status and patient survival.Cancer 46, 2765 (1980).

    Article  PubMed  CAS  Google Scholar 

  188. Leake R, Laing L, McArdle C, Smith D: Soluble and nuclear oestrogen receptor status in human breast cancer in relation to prognosis.Br J Cancer 43, 67 (1981).

    PubMed  CAS  Google Scholar 

  189. Hilf R, Feldstein M, Gibson S, Savlov E: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer.Cancer 45, 1993 (1980).

    Article  PubMed  CAS  Google Scholar 

  190. Gallagher H: Current controversies in breast cancer, presented at M. D. Anderson, 3–5 November (1982).

  191. Nissen-Meyer R, Kjellgren K, Mansson B: Adjuvant chemotherapy in breast cancer, in Mathé G, Bonadonna G, Salmon S (eds)Recent Results in Cancer Research. Adjuvant Therapies of Cancer,pp. 142–148. Berlin, Springer. (1982).

    Google Scholar 

  192. Fisher B, Redmond C, Fisher E: The contribution at recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology—an overview of findings.Cancer 46, 1009 (1980).

    Article  PubMed  CAS  Google Scholar 

  193. Rubens R, Knight R, Fentiman I, Howell A, Crowther D, George W, Hayward J, Balbrook R, Chandary M, Bush H, Sellwood R, Howat J: Controlled trial of adjuvant chemotherapy with melphalan for breast cancer.Lancet i, 839 (1983).

    Article  Google Scholar 

  194. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer.New Engl J Med 294, 405 (1976).

    PubMed  CAS  Google Scholar 

  195. Rossi A, Bonadonna G, Valagussa P, Veronesi U: Multimodal treatment in operable breast cancer: five-year results of the CMF programme.Br Med J 282, 1427 (1981).

    CAS  Google Scholar 

  196. Bonadonna G, Valagussi P: Dose-response effect of adjuvant chemotherapy in breast cancer.New Engl J Med 304, 10 (1981).

    PubMed  CAS  Google Scholar 

  197. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles.J Clin Oncol 1, 2 (1983).

    PubMed  CAS  Google Scholar 

  198. Velez-Garcia E, Moore M, Marcial V, Bartolucci A, Ketcham A, Smalley R: Adjuvant chemotherapy and radiotherapy in Stage II breast cancer.Proc ASCO 18, 80 (1982).

    Google Scholar 

  199. Cooper R, Holland J, Glidewell O: Adjuvant chemotherapy of breast cancer.Cancer 44, 793 (1979).

    Article  PubMed  CAS  Google Scholar 

  200. Holland J, Glidewell O, Cooper R: Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast.Surg Gynec Obst 150, 817 (1980).

    CAS  Google Scholar 

  201. Tormey D, Holland J, Weinberg V, Weiss R, Falkson G, Glidewell O, Leone L, Perloff M: 5-drug vs 3-dru ± MER postoperative chemotherapy for mammary carcinoma, inAdjuvant Therapy of Cancer, Salmon S. and Jones S. (eds), vol. III, pp. 377–384. New York, Grune & Stratton (1981).

    Google Scholar 

  202. Glucksberg H, Rivkin S, Rasmussen S, Tranum B, Gad-el-Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J, Vaughn C: Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes. A Southwest Oncology Group Study.Cancer 50, 423–434 (1982).

    Article  PubMed  CAS  Google Scholar 

  203. Rivkin S, Glucksberg H, Foulkes M: Adjuvant chemotherapy for operable breast cancer with positive axillary nodes.Proc ASCO 2, 100 (1983).

    Google Scholar 

  204. Allen H, Brooks R, Jones S, Chase E, Heuskinkveld R, Giordano G, Ketchel S, Jackson R, Davis S, Moon T, Salmon S: Adjuvant treatment for Stage II (node-positive) breast cancer with adriamycin, cyclophosphamide (AC) ± radiotherapy (XRT), in Salmon S and Jones S (eds)Adjuvant Therapy of Cancer, vol. III, pp. 453–462. New York, Grune & Stratton (1981).

    Google Scholar 

  205. Brooks R, Jones S, Salmon S, Chase E, Davis S, Moon T, Giordano G, Ketchel S: Doxorubicin and cyclophosphamide adjuvant therapy of node negative breast cancer.Proc ASCO 1, 85 (1982).

    Google Scholar 

  206. Ali M, Cheng R, Buzdar A, Ewer M, Haynie T: Non-invasive cardiac studies before and after adriamycin containing chemotherapy (FAC) for stages II and III breast cancer.Proc ASCO 1, 77 (1982).

    Google Scholar 

  207. Misset J, Delgado M, Plagne R, Belpomme D, Guerrin J, Fumoleau P, Metz R, Mathé G: Three year results of a randomized trial comparing CMF to adriamycin (ADM), vincristine (VCR), cyclophosphamide (CPM) and 5-fluorouracil (5-FU) (ACVF) as adjuvant therapy for operated N+breast cancer.Proc ASCO 1, 84 (1982).

    Google Scholar 

  208. Buzdar A, Blumenschein G, Smith T, Powell K, Hortobagyi G, Yap H, Hersh E: Adjuvant chemotherapy for breast cancer with fluorouracil, adriamycin, cyclophosphamide (FAC) with or without BCG and with or without postoperative radiation (XRT): a prospective randomized study.Proc AACR 23, 142 (1982).

    Google Scholar 

  209. Ravdin R, Lewison E, Slack N, Dao T, Gardner B, State D, Fisher B: Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma.Surg Gynec Obst 131, 1055 (1970).

    CAS  Google Scholar 

  210. Palshof T, Mouridsen H, Daehnfeldt S: Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen Breast Cancer Trials.Eur J Cancer (Suppl 1) 183 (1980).

    PubMed  CAS  Google Scholar 

  211. Fisher B, Redmond C, Brown A, Wolmark Net al: Treatment of primary breast cancer with chemotherapy and tamoxifen.New Engl J Med 305, 1 (1981).

    PubMed  CAS  Google Scholar 

  212. Hubay C, Pearson O, Marshall J, Rhodes R, De Banne R, Rosenblatt J, Mangone E, Hermann R, Jones J, Flynn W, Eckert C, McGuire W: Adjuvant chemotherapy for Stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial.Cancer 46, 2805 (1980).

    Article  PubMed  CAS  Google Scholar 

  213. Kardinal C, Donegan W: Second cancers after prolonged adjuvant thiotepa for operable carcinoma of the breast.Cancer 45, 2042 (1980).

    Article  PubMed  CAS  Google Scholar 

  214. Wendt A, Jones S, Salmon S: Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy.Cancer Treat Rep 64, 269 (1980).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neoplastic Diseases, Mt Sinai School of Medicine, 10029, New York, NY, U.S.A.

    Lawrence S. Perlow & James F. Holland

Authors
  1. Lawrence S. Perlow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James F. Holland
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perlow, L.S., Holland, J.F. Chemotherapy of breast cancer. Med. Oncol. & Tumor Pharmacother. 1, 169–192 (1984). https://doi.org/10.1007/BF02934139

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02934139

Keywords

Search

Navigation